Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. - Wikidata - awgldk - TriplyDB

Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study.

Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study.

http://www.wikidata.org/entity/Q42607619

about

Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg Reduced coronary flow reserve in Anderson-Fabry disease measured by transthoracic Doppler echocardiography.Enzyme replacement therapy for Anderson-Fabry disease Enzyme replacement therapy for Anderson-Fabry disease Long-term safety and efficacy of enzyme replacement therapy for Fabry disease Enzyme replacement therapy for Anderson-Fabry disease Is 2D speckle tracking echocardiography useful for detecting and monitoring myocardial dysfunction in adult m.3243A>G carriers? - a retrospective pilot study Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance Tissue Doppler and strain imaging: anything left in the echo-lab?Exercise training does not improve myocardial diastolic tissue velocities in Type 2 diabetes.Effects of enzyme replacement therapy in adult patients with Fabry disease on cardiac structure and function: a retrospective cohort study of the Fabry Munster Study (FaMuS) data Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry Registry.Arrhythmias in Fabry cardiomyopathy.Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity Enzyme replacement therapy for Fabry disease: some answers but more questions Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A).A disproportionate contribution of papillary muscles and trabeculations to total left ventricular mass makes choice of cardiovascular magnetic resonance analysis technique critical in Fabry disease Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.The natural history of left ventricular systolic function in Anderson-Fabry disease.Cellular and tissue distribution of intravenously administered agalsidase alfa.Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A The heart in Anderson-Fabry disease and other lysosomal storage disorders.The expanding clinical spectrum of Anderson-Fabry disease: a challenge to diagnosis in the novel era of enzyme replacement therapy.Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval.Normal left-atrial structure and function despite concentric left-ventricular remodelling in a cohort of patients with Anderson-Fabry disease.Does oxidative stress modulate left ventricular diastolic function in asymptomatic subjects with hereditary hemochromatosis?Fabry disease: incidence of the common later-onset α-galactosidase A IVS4+919G→A mutation in Taiwanese newborns--superiority of DNA-based to enzyme-based newborn screening for common mutations Cardiac magnetic resonance in myocardial disease Inflammation, ECG changes and pericardial effusion: whom to biopsy in suspected myocarditis?Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease Fabry disease: guidelines for the evaluation and management of multi-organ system involvement.Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease.Fabry cardiomyopathy.Novel therapeutic targets for the treatment of Fabry disease.Unexplained left ventricular hypertrophy: consider a diagnosis of Fabry's disease.Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A)High-Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease.Fibrosis: a key feature of Fabry disease with potential therapeutic implications

P2860

Q21004071-CD395368-37BD-4041-9823-C4EAE11A536C Q21245672-9A936728-5035-4B4F-A1D8-0512BA17502D Q24200877-6236003E-EF10-4810-AE95-3F7E5A3FF75D Q24235483-4CBFA3A8-17BE-4CD8-A1F3-810AE09DF059 Q24533551-996DC2C5-0CEE-402A-AF8C-BD621F8C3721 Q26471010-B5367804-91E6-496B-911D-889804AE1995 Q30362604-7123FCE7-C243-463A-BBCF-043499C8BA87 Q30423465-1AF3421F-41AA-401D-8948-C9966AE5ECCE Q30492698-BE2824A2-B808-4862-932A-D0E7F250427A Q30499724-B9045796-B321-46AD-A93B-01540FAC8D59 Q30578294-E2132BDD-435D-42D4-A022-0234C9AB80A5 Q30632134-E571A882-1B56-4A11-8C49-CF0F40E8007E Q33161649-4ADFD5D3-612C-442E-A532-835D35C5BD82 Q34030488-101F59C3-5438-438C-95AE-48CD5EC659E4 Q34703815-465C1D0C-3F1F-4E62-84EC-F8720F333D6E Q34805283-A53AC935-7B1B-47EC-94E8-6E1859C17133 Q34993215-53CDCECE-F149-42E7-A734-E556F9B5F811 Q35104405-B56B3C73-ED5E-449D-9838-51BDA68C2410 Q35560027-F40D7EE0-A1BD-4A9B-AB52-E97960AEF362 Q35584050-D8AC9FC6-70E5-465A-B0D7-88C0CDA2FFB4 Q35728693-70F54E57-C9B0-4EC7-B062-57075C55B293 Q35771337-60FF444A-49CC-4C1A-A9C4-671B217526FA Q35773435-2610B572-A63F-4B28-A76D-FCABF15DF9CB Q35775374-CAC3ADED-8A93-42B5-AEBD-EE055BBAEFF0 Q35842694-68F5B214-DFA0-4EB1-B482-6185B33F3760 Q36061578-C5900CC6-F610-4620-A665-6AE7280895DE Q36097772-10BE4E3F-E9D7-41BA-8204-96635ADD262E Q36130925-E3424881-FC3C-4FD7-BC80-1AA9EE0B7042 Q36498834-ACBF50D3-EC7A-4C23-A0AF-86B4B558DAAD Q36560495-FF7F1043-C69B-4D3A-99C4-CD22011DBAA8 Q36590934-3B9B7417-2A8A-4426-A0CA-89A712B3C42F Q36596408-7DA77A8F-AF4B-4A06-BB7F-3613310FFF40 Q36624746-B18E8565-DC6F-4988-A502-4C87FAD05294 Q36691040-770FFE70-3B48-4A86-8AEC-36428170E1C2 Q36725528-D514BB04-EAAA-4157-8C76-EC3F0A4F7148 Q36822452-A6553D44-72BD-447A-BA60-28E7AACA52D6 Q36917375-6A0CDB38-8CDB-4B49-9D6A-CABE047F5EE0 Q37029946-618474D5-5ACB-4A7F-9B57-2A176CD43B23 Q37076050-7415D6BB-9E16-465C-9B8A-112C9A2036F6 Q37113004-664D2C5B-1ED0-4354-AC1C-16D238795816

P2860

Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study.

http://www.wikidata.org/entity/Q42607619

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Improvement of cardiac functio ...... ive strain rate imaging study.

@en

Improvement of cardiac functio ...... ive strain rate imaging study.

@nl

type

label

Improvement of cardiac functio ...... ive strain rate imaging study.

@en

Improvement of cardiac functio ...... ive strain rate imaging study.

@nl

prefLabel

Improvement of cardiac functio ...... ive strain rate imaging study.

@en

Improvement of cardiac functio ...... ive strain rate imaging study.

@nl

P1433

Q42607619-4CCC5F3D-E7DF-468E-BB11-F1E6A3B31C73

P1476

Q42607619-33CF9DEC-9935-416C-BBE7-ADD14CDC04C4

P2093

Q42607619-665E1A98-3234-469D-8AFB-86A0B545F4A3

Q42607619-95F73F8B-3DCF-46A0-9415-EF38F974AE82

Q42607619-9AB63A00-04AA-4F48-AE68-3EAE538DFC94

Q42607619-9DCE0FB8-AFE7-46FC-A934-0BC5BBC04AEA

Q42607619-A3FD0D09-CBCB-4DC6-B4A1-3C6BF1BD9A8E

Q42607619-B5AB8C36-D313-4120-BB41-9F3F4669254C

Q42607619-B82432D4-82BF-4763-B143-AFC70D19B3D7

Q42607619-BC31DA21-6B79-4DD1-80DB-62D41A01ED61

Q42607619-BE228FE0-A69E-479E-BE69-D76063D1BCDA

Q42607619-DAEEF112-1D85-41E2-8332-026827BCB52A

P304

Q42607619-1D11C36A-9BDA-4F59-BE5A-1E0768854DC7

P31

Q42607619-A5031F1F-1381-4614-8438-5AB2B91FC435

P356

Q42607619-FDC8FD22-44C5-44BF-8C4B-5002DCE5CBEB

P407

Q42607619-B147688A-E5F5-4255-A163-F01ED1892CB8

P433

Q42607619-F56A63C6-BD0A-4055-9F9E-FBA021637076

P478

Q42607619-EFD80FEF-8BA0-40FA-B908-B5A97293482B

P577

Q42607619-8C4A7063-6599-4228-8A2D-88A7BF5A321A

P698

Q42607619-663B759E-E054-470A-B986-3F2A2D02C639

P921

Q42607619-08F3248F-6825-49E2-8332-AFFDC88132B9

P356

01.CIR.0000091253.71282.04

P1433

P1476

Improvement of cardiac functio ...... ive strain rate imaging study.

@en

P2093

Anita Knoll

http://www.w3.org/2001/XMLSchema#string

Christoph Wanner

http://www.w3.org/2001/XMLSchema#string

Frank Breunig

http://www.w3.org/2001/XMLSchema#string

Frank Weidemann

http://www.w3.org/2001/XMLSchema#string

Georg Ertl

http://www.w3.org/2001/XMLSchema#string

Joern Sandstede

http://www.w3.org/2001/XMLSchema#string

Jörg M Strotmann

http://www.w3.org/2001/XMLSchema#string

Meinrad Beer

http://www.w3.org/2001/XMLSchema#string

Oliver Turschner

http://www.w3.org/2001/XMLSchema#string

Wolfram Voelker

http://www.w3.org/2001/XMLSchema#string

P304

1299-1301

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/01.CIR.0000091253.71282.04

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P577

2003-09-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12952834

http://www.w3.org/2001/XMLSchema#string

P921

Enzyme replacement therapy